DaVita (DVA) stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 64 to 72.
↑ XThis exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if DaVita stock can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Davita stock is currently trading below its 50-day moving average. While the stock is not near an ideal buying range right now, see if it goes on to form and break out from a proper base.
The kidney dialysis center operator reported -12% earnings growth in the latest quarterly report. Sales rose 5%.
Davita stock earns the No. 8 rank among its peers in the Medical-Outpatient/Home Care industry group. Addus HomeCare (ADUS), Encompass Health (EHC) and RadNet (RDNT) are among the top 5 highly rated stocks within the group.
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。